VEGFA and neoplasm: The availability of highly active chemotherapeutics and the approval of several targeted therapies, such as agents directed against the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) and its receptors, led to significant improvements in tumor response rates and survival in patients with mCRC [3].